Latest News

Arrowhead Pharmaceuticals: Pushing the Boundaries of Gene Silencing

RNA interference (RNAi), sometimes called gene silencing, is an approach to therapeutics in certain diseases that are caused by the production of abnormal proteins or an overproduction of proteins, which can be treated by turning off or silencing the
Read More

‘Grey’s Anatomy’ TV Show’s episode about Alpha-1

[Warning: The below contains MAJOR spoilers for Season 16, Episode 15 of Grey’s Anatomy, “Snowblind.”] The blizzard isn’t the only disaster in this Grey’s Anatomy episode—Season 16, Episode 15 Hayes’ patient this week is Elisa, a 6-year-old with alph
Read More

Alpha-1 Awareness donate £10,000 to the research of a cure

On Monday 3rd February 2020, Alan and Emma Wooler of Alpha-1 Awareness went to UCL (University College London) to see Professor David Lomas, and presented him with a cheque for £10,000 to go towards his research of a cure for Alpha-1.   Alan Woo
Read More

Researchers build a better lung model

30th January 2020   (Boston)–Using a combination of pluripotent stem cells (cells that can potentially produce any cell or tissue type) and machine learning (artificial intelligence that allows computers to learn automatically), researcher
Read More

Danish Medicines Council Grants Approval for CSL Behring’s Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

HATTERSHEIM AM MAIN, Germany, Jan. 24, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the Danish Medicines Council has published its final decision, approving human Alpha 1 Antitrypsin  (AAT) therapy and Resp
Read More

Dicerna™ Receives Orphan Drug Designation From European Commission for DCR-A1AT for Treatment of Congenital Alpha-1 Antitrypsin Deficiency

LEXINGTON, Mass.–(BUSINESS WIRE)–Dec. 17, 2019– Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today annou
Read More